4 assets in Mucopolysaccharidosis Type 6

Therapeutic assets addressing Mucopolysaccharidosis Type 6, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Busulfanum Mucopolysaccharidosis Type 6	Masonic Cancer Center, University of Minnesota	P2	B (61)
Cald Hr-D Mucopolysaccharidosis Type 6	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Adalimumab Mucopolysaccharidosis Type 6	Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center	P1/2	CCC (52)
Iduronidase, .Alpha.-L-(8-Histidine) (Human) Mucopolysaccharidosis Type 6	University of California, San Francisco	P1	CC (43)